Overzicht
Wijziging aandelenprijs
24u
Huidig
Min
1.23
Max
1.58
Inkomsten | -45M -67M |
|---|---|
Verkoop | -1.6M 33M |
EPS | -2.32 |
Winstmarge | -200.476 |
Werknemers | 228 |
EBITDA | -44M -54M |
Volgende Winsten | 2 nov 2026 |
|---|
Marktkapitalisatie | -3.8M 41M |
|---|---|
Vorige openingsprijs | 0.33 |
Vorige sluitingsprijs | 1.6 |
Nieuwssentiment
By Acuity
50%
50%
146 / 339 Rangschikking in Healthcare
Karyopharm Therapeutics Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
10 sep 2026, 20:07 UTC
Karyopharm Therapeutics is lower today, continuing a broader trend of weakness and remaining below its 20-day moving average. No specific news was identified.
Lezen
8 sep 2026, 20:07 UTC
Karyopharm Therapeutics shares are lower after downgrades from Robert W. Baird and HC Wainwright, with a target price set at $3.00.
Lezen
2 sep 2026, 20:08 UTC
Karyopharm Therapeutics Inc shares are lower today, having reached a session low earlier. The stock remains near the lower end of its one-month range.
Lezen
1 sep 2026, 20:01 UTC
Karyopharm Therapeutics submitted a supplemental New Drug Application for XPOVIO, but shares are trading lower amid broader market concerns about rising oil prices and interest rates.
Lezen
31 aug 2026, 20:02 UTC
Karyopharm Therapeutics submitted a supplemental New Drug Application for XPOVIO, seeking Accelerated Approval for myelofibrosis treatment. Shares are gaining during Monday's session.
Lezen
28 aug 2026, 20:08 UTC
Karyopharm Therapeutics Inc shares declined during Friday's session amid rising U.S. Treasury yields, reflecting broader market trends. The stock finished near its one-month low.
Lezen
25 aug 2026, 20:07 UTC
Karyopharm Therapeutics Inc shares are higher during Tuesday's session, reaching a peak earlier in the day. The stock remains below its 20-day moving average.
Lezen
24 aug 2026, 19:16 UTC
Karyopharm Therapeutics Inc shares are lower today, reaching a session low amid ongoing market weakness and no specific news to explain the decline.
Lezen
21 aug 2026, 23:51 UTC
Karyopharm Therapeutics Inc shares are lower in after-market hours, following a brief uptick earlier. No specific news was identified to explain the decline.
Lezen
20 aug 2026, 20:02 UTC
Karyopharm Therapeutics is declining sharply amid a significant downturn in the Biotechnology sub-sector, nearing the lower end of its one-month trading range.
Lezen
18 aug 2026, 20:03 UTC
Karyopharm Therapeutics Inc is trading higher today, continuing its upward trend since Monday's close. The stock remains below its 20-day moving average.
Lezen
17 aug 2026, 23:46 UTC
Karyopharm Therapeutics shares are higher in after-market hours, following volatility earlier. Broader market pressures include geopolitical tensions and rising crude oil prices.
Lezen
14 aug 2026, 23:51 UTC
Karyopharm Therapeutics shares are higher in after-market trading, despite no specific news. Broader market sentiment reflects concerns from a decline in U.S. retail sales.
Lezen
13 aug 2026, 23:11 UTC
Karyopharm Therapeutics Inc shares are rising in after-market trading, showing a modest upward trend since Thursday's close despite recent significant declines.
Lezen
12 aug 2026, 19:56 UTC
Karyopharm Therapeutics Inc shares are lower today, retracing from an early high amid broader market conditions and geopolitical tensions. No specific news was identified.
Lezen
11 aug 2026, 20:01 UTC
Karyopharm Therapeutics Inc is trading higher today, having reached a peak earlier in the session. The stock remains below its 20-day moving average.
Lezen
10 aug 2026, 20:06 UTC
Karyopharm Therapeutics Inc shares are lower today, reversing an early gain and reaching a mid-morning low, with no specific news identified for the decline.
Lezen
7 aug 2026, 23:31 UTC
Karyopharm Therapeutics shares are lower in after-market hours, following a decline earlier despite gains in major tech stocks. No specific news was identified.
Lezen
6 aug 2026, 23:21 UTC
Karyopharm Therapeutics Inc shares are lower in after-market hours. The asset is trading below its 20-day moving average and near the lower end of its one-month range.
Lezen
5 aug 2026, 23:01 UTC
Karyopharm Therapeutics shares are lower in after-market hours, continuing a three-session decline amid broader market weakness from disappointing U.S. employment data.
Lezen
4 aug 2026, 23:46 UTC
Karyopharm Therapeutics shares are higher in after-market trading, though no specific news explains the movement. Broader market optimism may be influencing risk assets.
Lezen
3 aug 2026, 23:41 UTC
Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.
Lezen
1 aug 2026, 00:01 UTC
Karyopharm Therapeutics Inc shares are higher in after-market hours, reaching their highest cumulative return of the day despite recent underperformance.
Lezen
31 jul 2026, 23:31 UTC
Karyopharm Therapeutics shares rose during after-market hours, continuing a recovery from an earlier low. The stock remains below its 20-day moving average.
Lezen
30 jul 2026, 23:41 UTC
Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.
Lezen
29 jul 2026, 19:27 UTC
Karyopharm Therapeutics shares are lower as investor anxiety rises following the Federal Reserve's decision to maintain interest rates amid global uncertainties.
Lezen
27 jul 2026, 19:07 UTC
Karyopharm Therapeutics Inc shares are lower during Monday's trading session, reflecting ongoing weakness and broader market trends amid declining crude oil prices.
Lezen
24 jul 2026, 19:42 UTC
Karyopharm Therapeutics Inc. shares are higher during Friday's session, continuing a notable advance since Thursday, despite broader market challenges.
Lezen
23 jul 2026, 09:01 UTC
Karyopharm Therapeutics Inc shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite recent volatility and no specific news.
Lezen
22 jul 2026, 18:41 UTC
Karyopharm Therapeutics shares are declining amid market caution and rising crude oil prices. RBC Capital reaffirmed its Outperform rating with a $16 price target.
Lezen
Peer Vergelijking
Prijswijziging
Karyopharm Therapeutics Inc Prognose
Beoordelingsconsensus
By TipRanks
Moderate Buy
6 ratings
4
Buy
2
Hold
0
Sell
Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.
Sentiment
By Acuity
Nieuwssentiment
Neutral
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Onder gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$